MG
CPRX

Mather Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Mather Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15K Hold
132
– – ﹤0.01% 1648
2026
Q1 		$3.27K Buy
+132
New +$3.15K ﹤0.01% 1637
2025
Q4 		– Sell
-132
Closed -$2.6K – 851
2025
Q3 		$2.6K Buy
+132
New +$2.71K ﹤0.01% 1501
2025
Q2 		– Sell
-132
Closed -$3.2K – 841
2025
Q1 		$3.2K Hold
132
– – ﹤0.01% 1487
2024
Q4 		$2.75K Hold
132
– – ﹤0.01% 1485
2024
Q3 		$2.62K Sell
132
-333
-72% -$6.17K ﹤0.01% 1426
2024
Q2 		$7.41K Buy
+465
New +$7.24K ﹤0.01% 1525

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mather Group's CPRX Position: Q2 2026 in Review

Mather Group held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 132 shares worth $4.15K. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Mather Group first reported a position in CPRX in Q2 2024 and has held it in 7 quarters since. The position peaked at $7.41K in Q2 2024. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Mather Group held 132 shares of Catalyst Pharmaceutical worth $4.15K as of Q2 2026.
  • Mather Group left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1648 holding.
  • Mather Group first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 7 quarters since.
  • Mather Group's Catalyst Pharmaceutical position peaked at $7.41K in Q2 2024.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.